LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

UroGen Pharma Ltd

Chiusa

7.34 44.2

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.09

Massimo

8.18

Metriche Chiave

By Trading Economics

Entrata

-6.3M

-44M

Vendite

-4.3M

20M

EPS

-0.92

Margine di Profitto

-216.466

Dipendenti

234

EBITDA

-6.2M

-37M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+295.53% upside

Dividendi

By Dow Jones

Utili prossimi

12 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-296M

223M

Apertura precedente

-36.86

Chiusura precedente

7.34

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bullish Evidence

UroGen Pharma Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 mag 2025, 19:39 UTC

I principali Market Mover

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

Confronto tra pari

Modifica del prezzo

UroGen Pharma Ltd Previsione

Obiettivo di Prezzo

By TipRanks

295.53% in crescita

Previsioni per 12 mesi

Media 20.33 USD  295.53%

Alto 36 USD

Basso 3 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per UroGen Pharma Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

5

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

9.625 / 11.64Supporto e resistenza

A breve termine

Very Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Neutral Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.